Wolf JM, Gubert Borges B, Pereira Fagundes P, de Souza V, Brenner A, Petek H, et al. Adverse drug events, comorbidities, and older age are statistically more prevalent in COVID-19 hospitalized patients treated with remdesivir than tocilizumab in a private hospital from southern Brazil. Clin Biomed Res [Internet]. 29º de novembro de 2023 [citado 28º de agosto de 2026];43(3). Disponível em: https://seer.ufrgs.br/index.php/hcpa/article/view/129384